Suppr超能文献

增强型肝细胞腺瘤及其在钆塞酸增强 MRI 中的与 FNH 鉴别

HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI.

机构信息

Klinik Für Radiologie, Campus Virchow-Klinikum, Charité - Universitätsmedizin Berlin, Augustenburger Platz 1, 13353, Berlin, Germany.

Berlin Institute of Health (BIH), Anna-Louisa-Karsch-Straße 2, 10178, Berlin, 10178, Germany.

出版信息

BMC Med Imaging. 2021 Feb 15;21(1):28. doi: 10.1186/s12880-021-00552-0.

Abstract

BACKGROUND

Recent studies provide evidence that hepatocellular  adenomas  (HCAs) frequently take up gadoxetic acid (Gd-EOB) during the hepatobiliary phase (HBP). The purpose of our study was to investigate how to differentiate between Gd-EOB-enhancing HCAs and focal nodular hyperplasias (FNHs). We therefore retrospectively included 40 HCAs classified as HBP Gd-EOB-enhancing lesions from a sample of 100 histopathologically proven HCAs in 65 patients. These enhancing HCAs were matched retrospectively with 28 FNH lesions (standard of reference: surgical resection). Two readers (experienced abdominal radiologists blinded to clinical data) reviewed the images evaluating morphologic features and subjectively scoring Gd-EOB uptake (25-50%, 50-75% and 75-100%) for each lesion. Quantitative lesion-to-liver enhancement was measured in arterial, portal venous (PV), transitional and HBP. Additionally, multivariate regression analyses were performed.

RESULTS

Subjective scoring of intralesional Gd-EOB uptake showed the highest discriminatory accuracies (AUC: 0.848 (R#1); 0.920 (R#2)-p < 0.001) with significantly higher uptake scores assigned to FNHs (Cut-off: 75%-100%). Typical lobulation and presence of a central scar in FNH achieved an accuracy of 0.750 or higher in at least one reader (lobulation-AUC: 0.809 (R#1); 0.736 (R#2); central scar-AUC: 0.595 (R#1); 0.784 (R#2)). The multivariate regression emphasized the discriminatory power of the Gd-EOB scoring (p = 0.001/OR:22.15 (R#1) and p < 0.001/OR:99.12 (R#2). The lesion-to-liver ratio differed significantly between FNH and HCA in the PV phase and HBP (PV: 132.9 (FNH) and 110.2 (HCA), p = 0.048 and HBP: 110.3 (FNH) and 39.2 (HCA), p < 0.001)), while the difference was not significant in arterial and transitional contrast phases (p > 0.05).

CONCLUSION

Even in HBP-enhancing HCA, characterization of Gd-EOB uptake was found to provide the strongest discriminatory power in differentiating HCA from FNH. Furthermore, a lobulated appearance and a central scar are more frequently seen in FNH than in HCA.

摘要

背景

最近的研究表明,肝细胞腺瘤(HCA)在肝胆期(HBP)经常摄取钆塞酸(Gd-EOB)。我们的研究目的是探讨如何区分 Gd-EOB 增强的 HCA 和局灶性结节增生(FNH)。因此,我们回顾性地纳入了 40 例 HCA,这些 HCA 在 65 例经病理证实的 100 例 HCA 中被归类为 HBP Gd-EOB 增强病变。这些增强的 HCA 与 28 例 FNH 病变(标准参考:手术切除)进行了回顾性匹配。两名(经验丰富的腹部放射科医生,对临床数据不知情)读者评估了图像的形态特征,并对每个病变的 Gd-EOB 摄取进行主观评分(25-50%、50-75%和 75-100%)。在动脉、门静脉(PV)、过渡和 HBP 期测量病变与肝脏的增强。此外,还进行了多变量回归分析。

结果

病变内 Gd-EOB 摄取的主观评分显示出最高的鉴别准确率(AUC:0.848(R#1);0.920(R#2)-p<0.001),FNH 的摄取评分明显更高(截断值:75%-100%)。FNH 中典型的分叶和中央瘢痕的存在在至少一名读者中达到了 0.750 或更高的准确率(分叶 AUC:0.809(R#1);0.736(R#2);中央瘢痕 AUC:0.595(R#1);0.784(R#2))。多变量回归强调了 Gd-EOB 评分的鉴别能力(p=0.001/OR:22.15(R#1)和 p<0.001/OR:99.12(R#2))。在门静脉期和 HBP 期,FNH 和 HCA 之间的病变与肝脏比值差异有统计学意义(PV:132.9(FNH)和 110.2(HCA),p=0.048 和 HBP:110.3(FNH)和 39.2(HCA),p<0.001)),而在动脉期和过渡期差异无统计学意义(p>0.05)。

结论

即使在 HBP 增强的 HCA 中,Gd-EOB 摄取的特征也被发现是区分 HCA 和 FNH 的最强鉴别力。此外,FNH 比 HCA 更常出现分叶状外观和中央瘢痕。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aa4/7885421/e22578e391fa/12880_2021_552_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验